Pulmonary Pharmacology and Therapeutics Pulmonary Pharmacology and Therapeutics RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements
Publication date: Available online 14 November 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Nagarjun Rangaraj, Sravanthi Reddy Pailla, Sunitha SampathiGraphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 15, 2018 Category: Respiratory Medicine Source Type: research

Prevalence of Arnold nerve reflex in subjects with and without chronic cough: Relevance to Cough Hypersensitivity Syndrome
ConclusionsThe greater than 11-fold prevalence of the Arnold nerve reflex in adults with chronic cough compared with healthy volunteers and adults with respiratory disease but without chronic cough, supports the concept of the Cough Hypersensitivity Syndrome (CHS), in which vagal hypersensitivity is proposed to underlie chronic refractory cough. The absence of increased prevalence among children with chronic cough suggests that CHS is an acquired condition, perhaps triggered by viral respiratory infection or other environmental factor. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 14, 2018 Category: Respiratory Medicine Source Type: research

Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study
Publication date: Available online 7 November 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Corrado Pelaia, Cecilia Calabrese, Sarah Barbuto, Maria Teresa Busceti, Mariaimmacolata Preianò, Luca Gallelli, Rocco Savino, Alessandro Vatrella, Girolamo PelaiaAbstractOmalizumab is a humanized monoclonal antibody which binds to human immunoglobulins E (IgE), thus preventing their interactions with both high affinity and low affinity IgE receptors. Therefore, omalizumab is currently recommended for add-on biological therapy of uncontrolled allergic asthma, mainly characterized by type 2 airway eosinophilic inflammat...
Source: Pulmonary Pharmacology and Therapeutics - November 8, 2018 Category: Respiratory Medicine Source Type: research

Varenicline for long term smoking cessation in patients with COPD
ConclusionsCOPD smokers had a similar response (higher tendency) to VT regardless of the presence of airflow obstruction and stronger nicotine addiction. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 3, 2018 Category: Respiratory Medicine Source Type: research

Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo
ConclusionPBD-617 not only inhibited TGF-β1-induced HELF proliferation, but also attenuated BLM-induced pulmonary fibrosis in rats, with efficacy to some extent higher than that of pirfenidone at the same effective dosage. PBD-617 attenuated pulmonary fibrosis effectively by suppressing activation of TGF-β1/Smad3 and p38 signaling pathways. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 29, 2018 Category: Respiratory Medicine Source Type: research

Inhaled calcium salts inhibit tobacco smoke-induced inflammation by modulating expression of chemokines and cytokines
Publication date: Available online 22 October 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Paulette W. Andreotta, Steve Arold, Jennifer Kenyon, Diane Spicer, Paul Woodman, Elizabeth Berry, Tim Brogan, Sophanna Kong, Pamela Okerholm, Vince Russell, Robert W. Clarke, David L. HavaAbstractTobacco smoke-induced lung inflammation in patients with chronic obstructive pulmonary disease (COPD) worsens with disease progression and acute exacerbations caused by respiratory infections. Chronic therapies to manage COPD center on bronchodilators to improve lung function and inhaled corticosteroids (ICS) to help reduce th...
Source: Pulmonary Pharmacology and Therapeutics - October 23, 2018 Category: Respiratory Medicine Source Type: research

Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases
Publication date: Available online 21 October 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Roberto Dal Negro, Edoardo Pozzi, Silvano G. CellaAbstractMucoactive drugs are commonly used in the treatment of acute respiratory tract diseases, such as lower and acute respiratory infection and chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD) in which an increased mucus secretion is one of main clinical features. Indeed these drugs are designed to promote secretion clearance and to specifically alter the viscoelastic properties of mucus, restoring an effective mucociliary clearance and reducin...
Source: Pulmonary Pharmacology and Therapeutics - October 21, 2018 Category: Respiratory Medicine Source Type: research

Oncogenic activity of insulin in the development of NSCLC: What is there behind the scenes?
Publication date: Available online 11 October 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Raffaella Mormile (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 12, 2018 Category: Respiratory Medicine Source Type: research

Aspirin use and racial differences in Non-Small cell lung cancer survival: What is the plot?
Publication date: Available online 11 October 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Raffaella Mormile (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 12, 2018 Category: Respiratory Medicine Source Type: research

Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations
We described the research areas in which HCU databases may be particularly useful, jointly with strength, weakness and potential of this approach. It is concluded that HCU data cannot substitute RCTs but they can usefully complement RCT data for adequately supporting healthcare decision-makers. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 5, 2018 Category: Respiratory Medicine Source Type: research

Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation
Publication date: Available online 4 October 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Sneha Dhapare, Masahiro SakagamiAbstractEmphysema causes progressive and life-threatening alveolar structural destruction/loss, yet remains irreversible and incurable to date. Impaired vascular endothelial growth factor (VEGF) signaling has been proposed as a new pathogenic mechanism, and if so, VEGF recovery may enable reversal of emphysema. Thus, we hypothesized that salvianolic acid B (Sal-B), a polyphenol in traditional Chinese herbal danshen, is an alveolar structural recovery agent for emphysema by virtue of VEGF ...
Source: Pulmonary Pharmacology and Therapeutics - October 5, 2018 Category: Respiratory Medicine Source Type: research

Andrographolide prevented toluene diisocyanate-induced occupational asthma and aberrant airway E-cadherin distribution via p38 MAPK-dependent Nrf2 induction
This study elucidates the therapeutic potential of AGP in the control and management of chemical-induced allergic asthma. To the best of our knowledge, the potential anti-asthma activity of AGP in TDI-induced occupational asthma has not been reported previously.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 22, 2018 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: October 2018Source: Pulmonary Pharmacology & Therapeutics, Volume 52Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 19, 2018 Category: Respiratory Medicine Source Type: research

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomised studies (DOROTHEO 1 and DOROTHEO 2)
Publication date: Available online 13 September 2018Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Luigino Calzetta, Nicola A. Hanania, Frank L. Dini, Marc F. Goldstein, William R. Fairweather, William W. Howard, Mario CazzolaAbstractThis pooled analysis of double-blind, randomized, placebo-controlled trials aimed to investigate the Impact of DOxofylline compaRed tO THEOphylline (DOROTHEO 1 and DOROTHEO 2 studies) on functional and clinical outcomes in asthma. Patients with asthma ≥16 years of age with (forced expiratory volume in 1 s [FEV1] ≥50% and <80% and with ≥15% post-bronchodilator increase in F...
Source: Pulmonary Pharmacology and Therapeutics - September 15, 2018 Category: Respiratory Medicine Source Type: research

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects
ConclusionsThe addition of FF 10 μg to GP MDI 28.8 μg or 14.4 μg in a fixed-dose combination did not appreciably alter the PK of GP, nor did an increase in GP dose from 14.4 μg to 28.8 μg in a fixed-dose combination with FF 10 μg appreciably alter the PK of formoterol. Both formulations of GFF MDI and GP MDI were well tolerated in healthy Japanese subjects. Data from this study support further evaluation of GFF MDI in Japanese patients with COPD. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 14, 2018 Category: Respiratory Medicine Source Type: research